Artemisinin and Its Derivatives in Cancer: A Mechanistic Review
Cancer Bioscience · 2026-05 · 100002
DOI: 10.1016/j.cbs.2026.100002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Bioscience, 2026-05. Verfasst von Zhentao Liang und 4 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 232 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Artemisinin and its derivatives (ARTs) have attracted increasing interest in oncology as candidates for drug repurposing, supported primarily by broad antitumor activity in preclinical models and only limited early clinical evidence. In this review, we organize the available literature into ten recurrent and partly overlapping mechanistic dimensions, including redox disruption, direct target engagement, epigenetic, post-transcriptional and post-translational regulation, metabolic reprogramming, induction of multiple tumor-cell death programs, proliferation restraint, inhibition of angiogenesis, suppression of invasion and metastasis, remodeling of the tumor immune microenvironment, and therapeutic sensitization. Current evidence further suggests that dysregulated heme metabolism and iron handling in malignant cells may provide a recurrent upstream biochemical context for endoperoxide activation, oxidative stress, and target perturbation. These upstream events are linked to diverse downstream effects on tumor survival, proliferative capacity, metastatic behavior, immune regulation, and treatment response, supporting a view of ARTs as pleiotropic and context-dependent modulators of tumor biology rather than agents acting through a single dominant downstream mechanism. This mechanistic breadth may help explain their reported activity across diverse malignancies and their ability to enhance sensitivity to chemotherapy, radiotherapy, targeted therapy, and immunotherapy in preclinical settings. However, clinical translation remains constrained by incomplete mechanistic resolution, context-dependent heterogeneity, the lack of robust predictive biomarkers, and pharmacokinetic as well as delivery limitations. Overall, this review provides a structured overview of the anticancer pharmacology of ARTs and highlights future priorities in biomarker development, patient stratification, and rational combination strategies.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liang, Z., Xie, W., Zhang, L., Sun, Y., & Wang, J. (2026). Artemisinin and Its Derivatives in Cancer: A Mechanistic Review. Cancer Bioscience, 100002. https://doi.org/10.1016/j.cbs.2026.100002
Vancouver
Liang Z, Xie W, Zhang L, Sun Y, Wang J. Artemisinin and Its Derivatives in Cancer: A Mechanistic Review. Cancer Bioscience. 2026:100002. doi:10.1016/j.cbs.2026.100002
BibTeX
@article{Liang2026,
author = {Liang, Zhentao and Xie, Wenqi and Zhang, Le-Le and Sun, Yang and Wang, Jigang},
title = {Artemisinin and Its Derivatives in Cancer: A Mechanistic Review},
journal = {Cancer Bioscience},
year = {2026},
pages = {100002},
doi = {10.1016/j.cbs.2026.100002}
}
EUVIMED